SAB Biotherapeutics, Inc.
SABS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $21 | $16 | $13 | $35 |
| - Cash | $29 | $4 | $6 | $9 |
| + Debt | $6 | $6 | $7 | $5 |
| Enterprise Value | -$2 | $19 | $14 | $31 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | -$1 | -$1 | -$1 | -$1 |
| % Margin | – | – | – | -585% |
| EBITDA | $46 | -$9 | -$4 | -$11 |
| % Margin | – | – | – | -9,187.7% |
| Net Income | $5 | -$10 | -$5 | -$11 |
| % Margin | – | – | – | -9,934.5% |
| EPS Diluted | -0.21 | -1.09 | -0.56 | -1.23 |
| % Growth | 80.7% | -94.6% | 54.5% | – |
| Operating Cash Flow | -$13 | -$7 | -$8 | -$9 |
| Capital Expenditures | $0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$13 | -$7 | -$8 | -$9 |